What's Going On With Chemomab Therapeutics Stock Today
Portfolio Pulse from Vandana Singh
Chemomab Therapeutics reported positive secondary Phase 2a liver fibrosis trial results for CM-101 in NASH patients. The data showed improvements in inflammatory and fibrotic biomarkers, with greater biomarker response in high-risk patients. CMMB shares are up 9.2% in premarket trading.
June 21, 2023 | 12:36 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Chemomab Therapeutics' positive Phase 2a trial results for CM-101 in NASH patients show improved biomarkers, leading to a 9.2% increase in CMMB shares during premarket trading.
The positive trial results indicate that CM-101 is showing promise in treating NASH patients, which could lead to increased demand for the drug and potential future revenue growth for Chemomab Therapeutics. This news has a direct impact on CMMB shares, as evidenced by the 9.2% increase in premarket trading.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100